Quarterly ResultMay 5, 2026, 06:21 AM
Integra LifeSciences Q1 Adj. EPS $0.54; Raises FY26 Adj. EPS Guidance
AI Summary
Integra LifeSciences Holdings Corporation reported its first quarter 2026 financial results, with revenues reaching $391.9 million, an increase of 2.4% on a reported basis and 1.3% organically year-over-year. The company saw an improvement in GAAP diluted EPS to $(0.06) from $(0.33) in the prior year, while adjusted diluted EPS rose to $0.54 from $0.41. Integra LifeSciences reaffirmed its full-year 2026 revenue guidance and raised its adjusted EPS guidance to a range of $2.40 to $2.50, citing benefits from IEEPA tariffs and improved operational performance.
Key Highlights
- Q1 2026 revenues were $391.9 million, up 2.4% reported and 1.3% organic year-over-year.
- Q1 2026 GAAP diluted EPS was $(0.06), an improvement from $(0.33) in Q1 2025.
- Q1 2026 Adjusted diluted EPS was $0.54, up from $0.41 in Q1 2025.
- Full-year 2026 revenue guidance reaffirmed at $1.662 billion to $1.702 billion.
- Full-year 2026 adjusted EPS guidance updated to $2.40-$2.50 from $2.30-$2.40.
- Specialty Surgery segment revenues were $283.1 million, up 0.9% reported, down (0.6)% organic.
- Tissue Reconstruction segment revenues were $108.8 million, up 6.7% reported and 6.4% organic.
- Net debt at quarter-end was $1.6 billion, with total liquidity of approximately $488 million.
Price Impact
More from IART